EP0881910A4 - Utilisation d'immunoconjugues pour accroitre l'efficacite des vaccins multietapes stimulant les reactions immunitaires en cascade - Google Patents

Utilisation d'immunoconjugues pour accroitre l'efficacite des vaccins multietapes stimulant les reactions immunitaires en cascade

Info

Publication number
EP0881910A4
EP0881910A4 EP96943706A EP96943706A EP0881910A4 EP 0881910 A4 EP0881910 A4 EP 0881910A4 EP 96943706 A EP96943706 A EP 96943706A EP 96943706 A EP96943706 A EP 96943706A EP 0881910 A4 EP0881910 A4 EP 0881910A4
Authority
EP
European Patent Office
Prior art keywords
immunoconjugates
efficacy
enhance
mammal
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP96943706A
Other languages
German (de)
English (en)
Other versions
EP0881910A1 (fr
Inventor
Hans J Hansen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunomedics Inc
Original Assignee
Immunomedics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/577,106 external-priority patent/US7354587B1/en
Application filed by Immunomedics Inc filed Critical Immunomedics Inc
Priority to EP09002533A priority Critical patent/EP2057999A3/fr
Publication of EP0881910A1 publication Critical patent/EP0881910A1/fr
Publication of EP0881910A4 publication Critical patent/EP0881910A4/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00118—Cancer antigens from embryonic or fetal origin
    • A61K39/001182—Carcinoembryonic antigen [CEA]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
EP96943706A 1995-12-22 1996-12-20 Utilisation d'immunoconjugues pour accroitre l'efficacite des vaccins multietapes stimulant les reactions immunitaires en cascade Ceased EP0881910A4 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP09002533A EP2057999A3 (fr) 1995-12-22 1996-12-20 Utilisation d'immunoconjugues pour accroitre l'efficacite des vaccins multietapes stimulant les reactions immunitaires en cascade

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/577,106 US7354587B1 (en) 1994-07-06 1995-12-22 Use of immunoconjugates to enhance the efficacy of multi-stage cascade boosting vaccines
US577106 1995-12-22
PCT/US1996/019755 WO1997023237A1 (fr) 1995-12-22 1996-12-20 Utilisation d'immunoconjugues pour accroitre l'efficacite des vaccins multietapes stimulant les reactions immunitaires en cascade

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP09002533A Division EP2057999A3 (fr) 1995-12-22 1996-12-20 Utilisation d'immunoconjugues pour accroitre l'efficacite des vaccins multietapes stimulant les reactions immunitaires en cascade

Publications (2)

Publication Number Publication Date
EP0881910A1 EP0881910A1 (fr) 1998-12-09
EP0881910A4 true EP0881910A4 (fr) 2006-05-03

Family

ID=24307306

Family Applications (2)

Application Number Title Priority Date Filing Date
EP96943706A Ceased EP0881910A4 (fr) 1995-12-22 1996-12-20 Utilisation d'immunoconjugues pour accroitre l'efficacite des vaccins multietapes stimulant les reactions immunitaires en cascade
EP09002533A Ceased EP2057999A3 (fr) 1995-12-22 1996-12-20 Utilisation d'immunoconjugues pour accroitre l'efficacite des vaccins multietapes stimulant les reactions immunitaires en cascade

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP09002533A Ceased EP2057999A3 (fr) 1995-12-22 1996-12-20 Utilisation d'immunoconjugues pour accroitre l'efficacite des vaccins multietapes stimulant les reactions immunitaires en cascade

Country Status (5)

Country Link
EP (2) EP0881910A4 (fr)
JP (2) JP2000503003A (fr)
AU (1) AU721927B2 (fr)
CA (1) CA2240834C (fr)
WO (1) WO1997023237A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080009171A (ko) * 1997-08-13 2008-01-24 더 유에이비 리서치 파운데이션 유전자 벡터의 국소 적용에 의한 백신접종
WO1999045018A1 (fr) * 1998-03-06 1999-09-10 Imclone Systems Incorporated Immunisation active contre les antigenes associes a l'angiogenese
WO1999059633A1 (fr) * 1998-05-20 1999-11-25 Immunomedics, Inc. Medicament renfermant un anticorps bispecifique antipathogene/anti-chaine invariante de la classe ii du systeme hla
US7074403B1 (en) * 1999-06-09 2006-07-11 Immunomedics, Inc. Immunotherapy of autoimmune disorders using antibodies which target B-cells
WO2001026672A1 (fr) * 1999-10-13 2001-04-19 Roswell Park Memorial Institute Induction d'une forte reponse immunitaire a un auto-antigene associe aux tumeurs
JP4212921B2 (ja) 2002-03-29 2009-01-21 独立行政法人科学技術振興機構 抗体を提示するタンパク質中空ナノ粒子を用いる治療薬剤およびタンパク質中空ナノ粒子
TWI434855B (zh) 2006-11-21 2014-04-21 Hoffmann La Roche 結合物及其在免疫分析中作為參考標準之用途
WO2009002159A2 (fr) 2007-05-31 2008-12-31 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Vaccin intradermique contenant un peptide de pvh
TWI438675B (zh) 2010-04-30 2014-05-21 Ibm 提供情境感知援助說明之方法、裝置及電腦程式產品
AU2012228100B2 (en) * 2011-03-17 2016-09-08 The University Of Birmingham Re-directed immunotherapy
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
US10040827B2 (en) 2012-03-19 2018-08-07 Deutsches Krebsforschungszentrum B-cell receptor complex binding proteins containing T-cell epitopes
GB201216649D0 (en) * 2012-09-18 2012-10-31 Univ Birmingham Agents and methods
EP3253419A1 (fr) 2015-02-02 2017-12-13 The University of Birmingham Complexes d'épitope de peptide de fragment de ciblage ayant une pluralité d'épitopes de lymphocyte t
WO2017087789A1 (fr) 2015-11-19 2017-05-26 Revitope Limited Complémentation de fragment d'anticorps fonctionnel pour un système à deux composants pour la destruction redirigée de cellules indésirables

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0324625A1 (fr) * 1988-01-12 1989-07-19 Bunge (Australia) Proprietary Limited Conjuqué anticorps-antigène
US5194254A (en) * 1986-05-06 1993-03-16 Connaught Laboratories Limited Enhancement of antigen immunogenicity
WO1996004313A1 (fr) * 1994-08-05 1996-02-15 Immunomedics, Inc. Immunoconjugues polyspecifiques et composites d'anticorps permettant le ciblage du phenotype multipharmacoresistant
WO1996037224A1 (fr) * 1995-05-25 1996-11-28 Ludwig Institute For Cancer Research Procedes de traitement du cancer du colon a l'aide d'anticorps specifiques de tumeur
WO1996040941A1 (fr) * 1995-06-07 1996-12-19 Connaught Laboratories Limited Anticorps chimeriques pour l'acheminement d'antigenes jusqu'a des cellules selectionnees du systeme immunitaire

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4036945A (en) 1976-05-03 1977-07-19 The Massachusetts General Hospital Composition and method for determining the size and location of myocardial infarcts
US4361549A (en) 1979-04-26 1982-11-30 Ortho Pharmaceutical Corporation Complement-fixing monoclonal antibody to human T cells, and methods of preparing same
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4818709A (en) 1983-01-21 1989-04-04 Primus Frederick J CEA-family antigens, Anti-CEA antibodies and CEA immunoassay
US5525338A (en) 1992-08-21 1996-06-11 Immunomedics, Inc. Detection and therapy of lesions with biotin/avidin conjugates
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
US4699784A (en) 1986-02-25 1987-10-13 Center For Molecular Medicine & Immunology Tumoricidal methotrexate-antibody conjugate
GB8610983D0 (en) * 1986-05-06 1986-06-11 Connaught Lab Enhancement of antigen immunogenicity
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
EP0438803B1 (fr) 1990-01-26 1997-03-12 Immunomedics, Inc. Vaccins contre le cancer et les maladies infectieuses
US5443953A (en) 1993-12-08 1995-08-22 Immunomedics, Inc. Preparation and use of immunoconjugates
JPH10500670A (ja) * 1994-05-13 1998-01-20 エクラゲン リミテッド ペプチド送達の改良またはペプチド送達との関連

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194254A (en) * 1986-05-06 1993-03-16 Connaught Laboratories Limited Enhancement of antigen immunogenicity
EP0324625A1 (fr) * 1988-01-12 1989-07-19 Bunge (Australia) Proprietary Limited Conjuqué anticorps-antigène
WO1996004313A1 (fr) * 1994-08-05 1996-02-15 Immunomedics, Inc. Immunoconjugues polyspecifiques et composites d'anticorps permettant le ciblage du phenotype multipharmacoresistant
WO1996037224A1 (fr) * 1995-05-25 1996-11-28 Ludwig Institute For Cancer Research Procedes de traitement du cancer du colon a l'aide d'anticorps specifiques de tumeur
WO1996040941A1 (fr) * 1995-06-07 1996-12-19 Connaught Laboratories Limited Anticorps chimeriques pour l'acheminement d'antigenes jusqu'a des cellules selectionnees du systeme immunitaire

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BECKER S: "Interferon-gamma accelerates immune proliferation via its effect on monocyte HLA - DR expression.", CELLULAR IMMUNOLOGY, (1985 MAR) 91 (1) 301-7., March 1985 (1985-03-01), XP000939351 *
BOHLEN H ET AL: "Idiotype vaccination strategies against a murine B-cell lymphoma: dendritic cells loaded with idiotype and bispecific idiotype x anti-class II antibodies can protect against tumor growth.", CYTOKINES AND MOLECULAR THERAPY, (1996 DEC) 2 (4) 231-8., December 1996 (1996-12-01), XP000946037 *
CARAYANNIOTIS G ET AL: "Delivery of synthetic peptides by anti-class II MHC monoclonal antibodies induces specific adjuvant-free Ig responses in vivo.", MOLECULAR IMMUNOLOGY, (1988 SEP) 25 (9) 907-11., September 1988 (1988-09-01), XP000939329 *
LOSMAN M J ET AL: "Human response against NP-4, a mouse antibody to carcinoembryonic antigen: human anti-idiotype antibodies mimic an epitope on the tumor antigen.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, (1991 APR 15) 88 (8) 3421-5., 15 April 1991 (1991-04-15), XP002147167 *
NEPOM G T ET AL: "Induction of immunity to a human tumor marker by in vivo administration of anti-idiotypic antibodies in mice.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, (1984 MAY) 81 (9) 2864-7., May 1984 (1984-05-01), XP002147166 *
See also references of WO9723237A1 *
YU Z ET AL: "Peptide-antibody conjugates for tumour therapy: a MHC-class-II-restricted tetanus toxin peptide coupled to an anti-Ig light chain antibody can induce cytotoxic lysis of a human B-cell lymphoma by specific CD4 T cells.", INTERNATIONAL JOURNAL OF CANCER, (1994 JAN 15) 56 (2) 244-8., 15 January 1994 (1994-01-15), XP000946044 *

Also Published As

Publication number Publication date
WO1997023237A1 (fr) 1997-07-03
EP2057999A3 (fr) 2009-07-29
JP2008115196A (ja) 2008-05-22
AU721927B2 (en) 2000-07-20
EP0881910A1 (fr) 1998-12-09
EP2057999A2 (fr) 2009-05-13
JP2000503003A (ja) 2000-03-14
AU1287197A (en) 1997-07-17
CA2240834A1 (fr) 1997-07-03
CA2240834C (fr) 2013-12-03

Similar Documents

Publication Publication Date Title
EP0881910A4 (fr) Utilisation d'immunoconjugues pour accroitre l'efficacite des vaccins multietapes stimulant les reactions immunitaires en cascade
RU95105991A (ru) Конъюгат, вакцина, способы усиления иммуногенности, способы иммунизации
HK1044564A1 (en) Agents, compositions and methods utilizing the same useful in treating or preventing alzheimer disease
DK0642355T3 (da) Kombinerede vacciner, der omfatter hepatitis B-overfladeantigen og andre antigener
IL132468A0 (en) A kit for inducing immune response against a tumor or a disease caused by an infection agent
CY1108307T1 (el) Αντιγονα και εμβολια εντεροκοκκου
BG98523A (en) Hla-limited cytotoxic t-lymphocytic (ctl) epitopes of the virus of hepatite b
NL300383I1 (nl) Gereconstitueerd menselijk antilichaam tegen menselijke interleukine 6-receptor
IL221708A0 (en) Polyclonal goat anti-hla class ii antibody for treatment of disease involving proliferative immune response
ATE233102T1 (de) Verfahren und zusammensetzung zur umgestaltung multi-epitopischer antigene um die immunantwort einzuleiten
HUP0302681A2 (hu) Protein antigének hősokk fehérjékhez való gerelyszerű hozzákötése
ES2096588T3 (es) Anticuerpos monoclonales para inducir tolerancia.
DK0536302T3 (da) Forbedrede adjuvanser og vacciner
WO2003083083A3 (fr) Procedes d'utilisation d'un ligand flt3 dans des protocoles d'immunisation
SE9604581D0 (sv) An agent against cancer and virus infections
DK0537168T3 (da) Antigenet CTAA 28A32, som genkendes af MCA 28A32
DE3851630D1 (de) Antikörper gegen streptococcus.
BR9306187A (pt) Vacina bacterin-toxóide pasteurella haemolytica tipo a-1
DE69322960D1 (de) Empfängnisverhütender impfstoff
EP0512023A4 (en) Medicaments and methods for treating aids and arc employing anti-carbohydrate antibodies and carbohydrate antigens
ATE348888T1 (de) Eine den gp41-zwischenzustand imitierende struktur bildendes polypeptid-antigen
MX9707295A (es) Metodo para mejorar la respuesta de los anticuerpos a los antigenos especificos con interleucina-10.
MX9300438A (es) Vacuna contra la estreptocinasa del streptococcus uberis.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19980721

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20060316

17Q First examination report despatched

Effective date: 20061121

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20091016